藥物基因體學市場商業機會、成長要素、產業趨勢分析及2026-2035年預測。

全球藥物基因體學市場預計到 2025 年將達到 57 億美元，年複合成長率為 10.6%，到 ​​2035 年將達到 154 億美元。

隨著基因資訊日益融入醫療系統的臨床決策流程，全球藥物基因體學市場正蓬勃發展。精準診斷的廣泛應用、多基因檢測技術的日益普及以及生物資訊學平台在個人化治療策略中的日益普及，是推動市場成長的主要因素。監管政策的進步、定序成本的下降以及人們對基於基因的處方益處的日益認可，都持續加速市場滲透。醫療機構越來越認知到藥物基因體學在改善治療效果、降低藥物相關風險以及最佳化醫療資源利用的價值。在多個治療領域不斷擴展的臨床應用，以及對基因組基礎設施投資的持續成長，為市場參與企業創造了巨大的機會。製藥公司、研究機構和醫療服務提供者正擴大將基因資訊納入藥物研發和病患管理流程。這些趨勢，加上持續的技術創新和不斷擴大的臨床應用，預計將在預測期內支撐全球藥物基因體學市場的持續成長。

預計到2025年，該產品細分市場將佔據67%的市場佔有率，並在2035年之前以10.5%的複合年成長率成長。此細分市場涵蓋廣泛的技術和解決方案，例如次世代定序系統、基於PCR的檢測產品、微陣列技術、檢體製備工具、生物資訊平台、伴隨診斷解決方案和檢查室自動化設備。對先進基因分析能力的日益成長的需求以及精準醫療工作流程的不斷普及，持續推動著該產品細分市場的強勁成長。

預計到2025年，醫院和診所領域的市佔率將達到37.9%，並在2035年之前以10.4%的複合年成長率成長。這個領域包括醫療機構、專科診所和私人執業者，他們擴大利用藥物基因體學檢測來支持個人化醫療決策。基因檢測日益融入常規醫療流程、臨床意識的提高以及對最佳化藥物選擇需求的成長，持續推動醫療服務提供者採用該技術。此外，人們越來越重視改善治療效果和減少藥物相關併發症，這也進一步促進了藥物基因體學學在醫院和診所環境中的應用。

預計到2025年，北美藥物基因體學市場佔有率將達到48.4%，並在2035年之前以10.4%的複合年成長率成長。該地區憑藉其強大的醫療保健基礎設施、先進的基因組學研究能力、支持性的法規結構以及精準醫療實踐的日益普及，保持著主導地位。美國是該地區成長的主要驅動力，這得益於藥物基因體學檢測臨床應用的不斷擴展、對基因組技術投資的增加以及將基因資訊整合到決策流程中。精準醫療系統的持續發展預計將進一步鞏固北美在全球市場的主導地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 精準醫療的需求日益成長
    • 藥物不良反應導致的負擔加重
    • 基因組技術的進步
    • 慢性病盛行率增加
    • 擴大藥物基因體學在藥物研發和臨床工作流程的應用
  • 產業潛在風險與挑戰
    • 與成本和還款相關的問題
    • 遺傳資料的複雜性解讀
  • 市場機遇
    • 基於微生物組的療法和荷爾蒙標靶療法的創新
    • 多基因檢測板和伴隨診斷的開發
• 成長潛力分析
• 技術與創新展望
  • 最新科技趨勢
  • 新興技術
• 監理情勢
• 波特的分析
• PESTLE分析
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估算與預測：依產品類型分類，2022-2035年

• 產品
  • 試劑盒和試劑
  • 裝置
• 服務

第6章 市場估計與預測：依技術分類，2022-2035年

• 定序
• PCR
• 微陣列
• 其他技術

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 個人化醫療
• 臨床研究
• 藥物發現與臨床前開發
• 其他用途

第8章 市場估計與預測：依疾病類別分類，2022-2035年

• 腫瘤學
• 心血管疾病
• 神經系統疾病
• 感染疾病
• 心理健康
• 其他疾病領域

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 醫院和診所
• 學術和研究機構
• 製藥和生物技術公司
• 受託研究機構（CRO）
• 其他最終用戶

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • UAE

第11章：公司簡介

• Admera Health
• Agilent Technologies Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Charles River Laboratories
• Danaher Corporation
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Genelex
• Genomind
• Illumina Inc.
• Labcorp Holdings Inc.
• Novogene Co., Ltd.
• OneOme
• Qiagen NV
• Revvity
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

The Global Pharmacogenomics Market was valued at USD 5.7 billion in 2025 and is estimated to grow at a CAGR of 10.6% to reach USD 15.4 billion by 2035.

The global pharmacogenomics market is witnessing momentum as healthcare systems increasingly integrate genetic insights into clinical decision-making processes. Market growth is supported by the rising adoption of precision diagnostics, expanding availability of multi-gene testing technologies, and increasing use of bioinformatics platforms that enable personalized treatment strategies. Regulatory advancements, declining sequencing costs, and growing awareness of the benefits associated with genetics-based prescribing continue to accelerate market adoption. Healthcare organizations are increasingly recognizing the value of pharmacogenomics in improving treatment outcomes, reducing medication-related risks, and optimizing healthcare resource utilization. Expanding clinical applications across multiple therapeutic areas, combined with growing investments in genomic infrastructure, continue to create significant opportunities for market participants. Pharmaceutical companies, research institutions, and healthcare providers are increasingly incorporating genetic information into drug development and patient management processes. These developments, along with continuous technological innovation and broader clinical accessibility, are expected to support the sustained growth of the global pharmacogenomics market throughout the forecast period.

The products segment held 67% share in 2025 and is projected to grow at a CAGR of 10.5% through 2035. The segment includes a wide range of technologies and solutions, such as next-generation sequencing systems, PCR-based testing products, microarray technologies, sample preparation tools, bioinformatics platforms, companion diagnostic solutions, and laboratory automation equipment. Increasing demand for advanced genetic analysis capabilities and expanding adoption of precision medicine workflows continue to drive strong growth within the product segment.

The hospitals and clinics segment held 37.9% share in 2025, growing at a CAGR of 10.4% through 2035. This segment includes healthcare institutions, specialty care facilities, and physician practices that increasingly utilize pharmacogenomic testing to support personalized treatment decisions. Growing integration of genetic testing into routine healthcare processes, increasing clinical awareness, and expanding demand for optimized drug selection continue to strengthen adoption among healthcare providers. The rising focus on improving treatment effectiveness and minimizing medication-related complications further supports the expansion of pharmacogenomics applications across hospitals and clinical environments.

North America Pharmacogenomics Market accounted for 48.4% share in 2025 and is forecast to grow at a CAGR of 10.4% through 2035. The region maintains its leadership position due to strong healthcare infrastructure, advanced genomic research capabilities, supportive regulatory frameworks, and increasing adoption of precision medicine practices. The United States represents the primary contributor to regional growth, supported by expanding clinical implementation of pharmacogenomic testing, increasing investments in genomic technologies, and growing integration of genetic information into healthcare decision-making processes. Continued development of precision healthcare systems is expected to reinforce North America's dominant position in the global market.

Major companies operating in the global pharmacogenomics market include Illumina, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Qiagen, Danaher Corporation, Agilent Technologies, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Charles River Laboratories, Eurofins Scientific, LabCorp, Revvity, Novogene Co., Ltd., Takara Bio Inc., Genomind, OneOme, Genelex, and Admera Health. Companies operating in the global pharmacogenomics market focus on technological innovation, strategic partnerships, and the expansion of precision medicine solutions to strengthen their market position. Leading organizations continue investing in research and development to improve genetic testing accuracy, sequencing capabilities, data analysis platforms, and clinical integration solutions. Many companies expand their offerings through advanced diagnostic products, customized testing services, and bioinformatics technologies designed to support personalized healthcare applications. Strategic collaborations with pharmaceutical companies, healthcare providers, and research institutions help accelerate innovation and broaden market adoption. Businesses also emphasize regulatory compliance, scalable testing infrastructure, and digital healthcare integration to enhance their competitive advantage.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Offering trends
  • 2.1.3 Technology trends
  • 2.1.4 Application trends
  • 2.1.5 Disease area trends
  • 2.1.6 End use trends
  • 2.1.7 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for precision medicine
    • 3.2.1.2 Rising burden of adverse drug reactions
    • 3.2.1.3 Advancements in genomic technologies
    • 3.2.1.4 Increasing prevalence of chronic diseases
    • 3.2.1.5 Increasing adoption of pharmacogenomics in drug development and clinical workflows
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Cost and reimbursement challenges
    • 3.2.2.2 Complexity and interpretation of genetic data
  • 3.2.3 Market opportunities
    • 3.2.3.1 Innovation in microbiome-based and hormone-targeted therapies
    • 3.2.3.2 Development of multi-gene panels and companion diagnostics
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Regulatory landscape (Driven by primary research)
  • 3.5.1 North America
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
  • 3.5.4 Latin America
  • 3.5.5 MEA
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends
• 3.9 Impact of AI and Generative AI on the market (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Offering, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Kits and reagents
  • 5.2.2 Instruments
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Sequencing
• 6.3 PCR
• 6.4 Microarray
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Personalized medicine
• 7.3 Clinical research
• 7.4 Drug discovery and preclinical development
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Disease Area, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Cardiovascular diseases
• 8.4 Neurological diseases
• 8.5 Infectious diseases
• 8.6 Mental health
• 8.7 Other disease areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Academic and research institutions
• 9.4 Pharmaceutical and biotechnology companies
• 9.5 Contract research organizations (CROs)
• 9.6 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Admera Health
• 11.2 Agilent Technologies Inc.
• 11.3 Becton, Dickinson and Company
• 11.4 Bio-Rad Laboratories Inc.
• 11.5 Charles River Laboratories
• 11.6 Danaher Corporation
• 11.7 Eurofins Scientific
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Genelex
• 11.10 Genomind
• 11.11 Illumina Inc.
• 11.12 Labcorp Holdings Inc.
• 11.13 Novogene Co., Ltd.
• 11.14 OneOme
• 11.15 Qiagen N.V.
• 11.16 Revvity
• 11.17 Takara Bio Inc.
• 11.18 Thermo Fisher Scientific Inc.